Association of Modifiable Risk Factors with Progression to Dementia in Relation to Amyloid and Tau Pathology

Overview

Journal Alzheimers Res Ther

Date 2024 Oct 27

PMID 39462394

Authors

Zsolt Huszar

Alina Solomon

Marie Anne Engh

Vanda Koszovacz

Tamas Terebessy

Zsolt Molnar

Peter Hegyi

Andras Horvath

Francesca Mangialasche

Miia Kivipelto

Gabor Csukly

Affiliations

Soon will be listed here.

Abstract

Background: Dementia preventive interventions targeting multiple modifiable risk factors are a promising approach. However, the impact of modifiable risk factors in the presence of beta-amyloid or phosphorylated-tau (p-tau) pathology is unclear.

Methods: The objective of the study was to examine the role of modifiable risk factors (vascular factors, depression, and smoking) in the progression to mild cognitive impairment (MCI) or dementia among 434 cognitively unimpaired (CU) and 611 individuals with MCI from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database. Vascular risk factors were summarized with the Cardiovascular Risk Factors, Aging, and Dementia (CAIDE) score, dichotomized into higher versus lower risk. Depression and smoking (yes/no) were categorised according to medical history or current symptoms. Analyses were stratified by beta-amyloid negative (A-) and positive (A +), p-tau negative (T-) and positive (T +), or beta-amyloid and p-tau negative (A-T-) and positive (A + T +) biomarker status. Cox proportional hazard models were adjusted for age, sex, education, baseline MMSE score, baseline hippocampal volume and ApoE4 carrier status.

Results: Higher CAIDE score was associated with increased risk of progression to all-cause dementia in most MCI subgroups: adjusted hazard ratios (aHR) [95% CI] were 3.1 [1.43; 6.53] in the A- subgroup, 1.7 [1.20-2.27] in T + , 2.6 [1.06-6.59] in A-T-, and 1.6 [1.15-2.22] in the A + T + subgroup. Smoking (yes/no) was associated with increased dementia aHR in the A + MCI subgroup: 1.6 [1.07-2.34]. Depression increased dementia aHR in the T + MCI subgroup: 1.5 [1.06-2.02]. No significant associations were found in the CU biomarker subgroups.

Conclusion: Addressing modifiable risk factors carries an important potential for reducing the risk of dementia even after the onset of Alzheimer's pathology. Knowledge of biomarker status can further optimize prevention strategies.

References

Dong J, Zhang Y, Tong J, Qin L . Depression and risk of stroke: a meta-analysis of prospective studies. Stroke. 2011; 43(1):32-7. DOI: 10.1161/STROKEAHA.111.630871. View

Gariepy G, Honkaniemi H, Quesnel-Vallee A . Social support and protection from depression: systematic review of current findings in Western countries. Br J Psychiatry. 2016; 209(4):284-293. DOI: 10.1192/bjp.bp.115.169094. View

Chhetri J, De Souto Barreto P, Cantet C, Pothier K, Cesari M, Andrieu S . Effects of a 3-Year Multi-Domain Intervention with or without Omega-3 Supplementation on Cognitive Functions in Older Subjects with Increased CAIDE Dementia Scores. J Alzheimers Dis. 2018; 64(1):71-78. DOI: 10.3233/JAD-180209. View

Peters M, Rosenberg P, Steinberg M, Norton M, Welsh-Bohmer K, Hayden K . Neuropsychiatric symptoms as risk factors for progression from CIND to dementia: the Cache County Study. Am J Geriatr Psychiatry. 2013; 21(11):1116-24. PMC: 3525756. DOI: 10.1016/j.jagp.2013.01.049. View

Brendel M, Pogarell O, Xiong G, Delker A, Bartenstein P, Rominger A . Depressive symptoms accelerate cognitive decline in amyloid-positive MCI patients. Eur J Nucl Med Mol Imaging. 2015; 42(5):716-24. PMC: 5849231. DOI: 10.1007/s00259-014-2975-4. View

Vuorinen M, Spulber G, Damangir S, Niskanen E, Ngandu T, Soininen H . Midlife CAIDE dementia risk score and dementia-related brain changes up to 30 years later on magnetic resonance imaging. J Alzheimers Dis. 2014; 44(1):93-101. DOI: 10.3233/JAD-140924. View

Ockene I, Miller N . Cigarette smoking, cardiovascular disease, and stroke: a statement for healthcare professionals from the American Heart Association. American Heart Association Task Force on Risk Reduction. Circulation. 1997; 96(9):3243-7. DOI: 10.1161/01.cir.96.9.3243. View

Jack Jr C, Bennett D, Blennow K, Carrillo M, Dunn B, Budd Haeberlein S . NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018; 14(4):535-562. PMC: 5958625. DOI: 10.1016/j.jalz.2018.02.018. View

Brown W, Thore C . Review: cerebral microvascular pathology in ageing and neurodegeneration. Neuropathol Appl Neurobiol. 2010; 37(1):56-74. PMC: 3020267. DOI: 10.1111/j.1365-2990.2010.01139.x. View

10.

Byers A, Yaffe K . Depression and risk of developing dementia. Nat Rev Neurol. 2011; 7(6):323-31. PMC: 3327554. DOI: 10.1038/nrneurol.2011.60. View

11.

Hansson O, Seibyl J, Stomrud E, Zetterberg H, Trojanowski J, Bittner T . CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimers Dement. 2018; 14(11):1470-1481. PMC: 6119541. DOI: 10.1016/j.jalz.2018.01.010. View

12.

Kuo C, Stachiv I, Nikolai T . Association of Late Life Depression, (Non-) Modifiable Risk and Protective Factors with Dementia and Alzheimer's Disease: Literature Review on Current Evidences, Preventive Interventions and Possible Future Trends in Prevention and Treatment of.... Int J Environ Res Public Health. 2020; 17(20). PMC: 7602449. DOI: 10.3390/ijerph17207475. View

13.

Shu S, Woo B . Use of technology and social media in dementia care: Current and future directions. World J Psychiatry. 2021; 11(4):109-123. PMC: 8040150. DOI: 10.5498/wjp.v11.i4.109. View

14.

Stephen R, Liu Y, Ngandu T, Rinne J, Kemppainen N, Parkkola R . Associations of CAIDE Dementia Risk Score with MRI, PIB-PET measures, and cognition. J Alzheimers Dis. 2017; 59(2):695-705. PMC: 5523839. DOI: 10.3233/JAD-170092. View

15.

Ngandu T, Lehtisalo J, Solomon A, Levalahti E, Ahtiluoto S, Antikainen R . A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015; 385(9984):2255-63. DOI: 10.1016/S0140-6736(15)60461-5. View

16.

Diniz B, Butters M, Albert S, Dew M, Reynolds 3rd C . Late-life depression and risk of vascular dementia and Alzheimer's disease: systematic review and meta-analysis of community-based cohort studies. Br J Psychiatry. 2013; 202(5):329-35. PMC: 3640214. DOI: 10.1192/bjp.bp.112.118307. View

17.

Walker K, Power M, Gottesman R . Defining the Relationship Between Hypertension, Cognitive Decline, and Dementia: a Review. Curr Hypertens Rep. 2017; 19(3):24. PMC: 6164165. DOI: 10.1007/s11906-017-0724-3. View

18.

Johnson A, Nystrom N, Piper M, Cook J, Norton D, Zuelsdorff M . Cigarette Smoking Status, Cigarette Exposure, and Duration of Abstinence Predicting Incident Dementia and Death: A Multistate Model Approach. J Alzheimers Dis. 2021; 80(3):1013-1023. PMC: 8044009. DOI: 10.3233/JAD-201332. View

19.

Clark C, Schneider J, Bedell B, Beach T, Bilker W, Mintun M . Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA. 2011; 305(3):275-83. PMC: 7041965. DOI: 10.1001/jama.2010.2008. View

20.

Peters R, Poulter R, Warner J, Beckett N, Burch L, Bulpitt C . Smoking, dementia and cognitive decline in the elderly, a systematic review. BMC Geriatr. 2008; 8:36. PMC: 2642819. DOI: 10.1186/1471-2318-8-36. View